{
  "title": "What this review means",
  "includeSubclaimIllustrations": false,
  "redteamReviewed": true,
  "accessNotice": "Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.",
  "overview": "Partial reprogramming has genuine preclinical functional benefits and an early human ocular trial; controlled human healthspan benefit and broad long-term safety remain unestablished.",
  "implications": "The preregistered adult-human clinical-healthspan primary remains Γ with Moderate confidence. Direct original-body checks preserve real preclinical function and lifespan benefits while preventing cells, xenografts or remaining mouse lifespan from being presented as treated-human outcomes. A verified first-in-human ER-100 study and sponsor interim signal make this an active translational programme, not an established clinical result. The post-discovery nongating preclinical SC5 receives Ε within its exact experimental contexts.",
  "limitations": "69 primary reports with 5 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation."
}